What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view. #plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY